Company · CIK 0001681087 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
Tectonic Therapeutic, Inc. · TECX
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2026 SForm 4 → | Aug 26, 4:30 pm EDT | Peter McNamaraChief Scientific Officer | 43 | $36.52 | $1,570 | 55,285 | −0.08% | 10b5-1 |
| Aug 25, 2026 MForm 4 → | Aug 26, 4:30 pm EDT | Peter McNamaraChief Scientific Officer | 43 | $14.71 | $633 | 55,328 | — | 10b5-1 |
| Aug 12, 2026 SForm 4 → | Aug 14, 7:25 pm EDT | Peter McNamaraChief Scientific Officer | 43 | $35.00 | $1,505 | 55,285 | −0.08% | 10b5-1 |
| Aug 12, 2026 MForm 4 → | Aug 14, 7:25 pm EDT | Peter McNamaraChief Scientific Officer | 43 | $14.71 | $633 | 55,328 | — | 10b5-1 |
| Jun 30, 2026 SForm 4 → | Jul 1, 5:19 pm EDT | Peter McNamaraChief Scientific Officer | 172 | $35.00 | $6,020 | 55,285 | −0.31% | 10b5-1 |
| Jun 30, 2026 MForm 4 → | Jul 1, 5:19 pm EDT | Peter McNamaraChief Scientific Officer | 172 | $14.71 | $2,530 | 55,457 | — | 10b5-1 |
| Jun 20, 2026 FForm 4 → | Jun 23, 5:52 pm EDT | Alise ReicinChief Executive Officer, Director | 924 | $30.34 | $28,034 | 310,623 | — |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 AForm 4 → | Sep 8, 4:45 pm EDT | Marc SchwabishChief Business Officer | 17,750 | — | — | 17,750 | — | |
| Sep 3, 2026 AForm 4 → | Sep 8, 4:45 pm EDT | Peter McNamaraChief Scientific Officer | 21,000 | — | — | 21,000 | — | |
| Sep 3, 2026 AForm 4 → | Sep 8, 4:45 pm EDT | Daniel LochnerChief Financial Officer | 24,250 | — | — | 24,250 | — | |
| Sep 3, 2026 AForm 4 → | Sep 8, 4:45 pm EDT | Marcella K. RuddyChief Medical Officer | 24,250 | — | — | 24,250 | — | |
| Sep 3, 2026 AForm 4 → | Sep 8, 4:45 pm EDT | Alise ReicinChief Executive Officer, Director | 69,250 | — | — | 69,250 | — | |
| Aug 25, 2026 MForm 4 → | Aug 26, 4:30 pm EDT | Peter McNamaraChief Scientific Officer | 43 | — | — | 7,787 | — | 10b5-1 |
| Aug 12, 2026 MForm 4 → | Aug 14, 7:25 pm EDT | Peter McNamaraChief Scientific Officer | 43 | — | — | 7,830 | — | 10b5-1 |
| Jun 30, 2026 MForm 4 → | Jul 1, 5:19 pm EDT | Peter McNamaraChief Scientific Officer | 172 | — | — | 7,873 | — | 10b5-1 |
| Jun 11, 2026 AForm 4 → | Jun 12, 4:30 pm EDT | Daniel LochnerChief Financial Officer | 7,500 | — | — | 7,500 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 4:45 pm EDT | Timothy A SpringerDirector, 10% Owner | 10,200 | — | — | 10,200 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 4:45 pm EDT | Praveen P. TipirneniDirector | 10,200 | — | — | 10,200 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 4:45 pm EDT | Phillip B. DonenbergDirector | 10,200 | — | — | 10,200 | — | |
| Jun 9, 2026 AForm 4 → | Jun 10, 4:45 pm EDT | Stefan VitorovicDirector | 10,200 | — | — | 10,200 | — | |
| Jun 8, 2026 AForm 4 → | Jun 10, 4:36 pm EDT | Jessica Caroline ChutterDirector | 20,400 | — | — | 20,400 | — |